NEW YORK, Aug. 9, 2014 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. reminds all purchasers of Prosensa Holding NV (Nasdaq:RNA) ordinary shares of the important September 16, 2014 lead plaintiff deadline in the class action.
To join the Prosensa class action, visit the firm's website at http://rosenlegal.com/cases-203.html or call Phillip Kim or Kevin Chan toll-free at 866-767-3653; you may also email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY CHOOSE TO DO NOTHING AT THIS POINT AND REMAIN AN ABSENT CLASS MEMBER.
According the lawsuit, the IPO Registration Statement contained inaccurate statements of material fact about the development status of drisapersen, the drug's Phase II and Phase III clinical studies, and the prospects for drisapersen's regulatory approval. Less than three months after the IPO, Prosensa disclosed that drisapersen had not met the primary endpoint in the Phase III study. According to the press release, "[t]here was no treatment difference in key secondary assessments of motor function: 10-meter walk/run test, 4-stair climb and North Star Ambulatory Assessment." On this news, the value of Prosensa stock dropped 70%.
If you wish to serve as lead plaintiff, you must move the Court no later than September 16, 2014. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of The Rosen Law Firm, toll-free, at 866-767-3653, or via e-mail at pkim@rosenlegal.com or kchan@rosenlegal.com. You may also visit the firm's website http://rosenlegal.com/cases-203.html.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.